tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Bill Maughan, 12 are a BUY (66.67%), 6 are a HOLD (33.33%).
Analyst Bill Maughan, currently employed at CANACCORD, carries an average stock price target met ratio of 44.44% that have a potential upside of 59.06% achieved within 180 days.
Bill Maughan’s has documented 35 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on FATE, Fate Therapeutics at 10-May-2024.
Analyst best performing recommendations are on DCTH (DELCATH SYSTEMS).
The best stock recommendation documented was for IMCR (IMMUNOCORE HOLDINGS LTD) at 2/29/2024. The price target of $63 was fulfilled within 8 days with a profit of $4.22 (6.28%) receiving and performance score of 7.85.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 10-Dec-2021
$30
$19.79 (193.83%)
$30
2 days ago
(09-Jan-2026)
3/16 (18.75%)
$19.79 (193.83%)
715
Buy
Since 05-Jan-2021
$23
$12.79 (125.27%)
$22
2 months 7 days ago
(04-Nov-2025)
1/5 (20%)
$13.48 (141.60%)
36
Buy
Since 09-Mar-2021
$21
$10.79 (105.68%)
$18
2 years 4 months 4 days ago
(07-Sep-2023)
2/5 (40%)
$16.4 (356.52%)
716
Buy
Since 04-Jun-2020
$13
$2.79 (27.33%)
$25
2 years 4 months 26 days ago
(16-Aug-2023)
2/4 (50%)
$7.59 (140.30%)
382
Buy
Since 26-Jul-2022
$14
$3.79 (37.12%)
$17
3 years 1 months 21 days ago
(21-Nov-2022)
2/2 (100%)
$11.06 (376.19%)
907
What Year was the first public recommendation made by Bill Maughan?
